TrialDiabetes care2018
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
124 papers cite itlatest 60 shown
this paperpooled ittrialcites it